Suscribirse

A mechanistic target of rapamycin complex 1/2 (mTORC1)/V-Akt murine thymoma viral oncogene homolog 1 (AKT1)/cathepsin H axis controls filaggrin expression and processing in skin, a novel mechanism for skin barrier disruption in patients with atopic dermatitis - 19/04/17

Doi : 10.1016/j.jaci.2016.09.052 
Aishath S. Naeem, PhD a, b, Cristina Tommasi, MRes a, b, Christian Cole, PhD c, Stuart J. Brown, PhD a, b, Yanan Zhu, PhD a, b, Benjamin Way, MA, BMBCh, MSc, MRCS a, b, Saffron A.G. Willis Owen, DPhil d, Miriam Moffatt, DPhil d, William O. Cookson, DPhil d, John I. Harper, MBBS, MD, FRCP, FRCPCH a, b, Wei-Li Di, PhD a, b, Sara J. Brown, MD, FRCPE e, Thomas Reinheckel, PhD f, Ryan F.L. O'Shaughnessy, PhD a, b,
a Immunobiology and Dermatology, UCL Institute of Child Health, London, United Kingdom 
b Livingstone Skin Research Centre, UCL Institute of Child Health, London, United Kingdom 
c Computational Biology, School of Life Sciences, University of Dundee, Dundee, United Kingdom 
e Centre for Dermatology and Genetic Medicine, Medical Research Institute, University of Dundee, Dundee, United Kingdom 
d National Heart and Lung Institute, Imperial College, London, United Kingdom 
f Institute of Molecular Medicine and Cell Research, BIOSS Centre of Biological Signalling Studies, Albert-Ludwigs-University, Freiburg, Germany 

Corresponding author: Ryan F. L. O'Shaughnessy, PhD, Immunobiology, UCL Institute of Child Health, 30 Guilford St, London WC1N 1EH, United Kingdom.Immunobiology, UCL Institute of Child Health30 Guilford StLondonWC1N 1EHUnited Kingdom

Abstract

Background

Filaggrin, which is encoded by the filaggrin gene (FLG), is an important component of the skin's barrier to the external environment, and genetic defects in FLG strongly associate with atopic dermatitis (AD). However, not all patients with AD have FLG mutations.

Objective

We hypothesized that these patients might possess other defects in filaggrin expression and processing contributing to barrier disruption and AD, and therefore we present novel therapeutic targets for this disease.

Results

We describe the relationship between the mechanistic target of rapamycin complex 1/2 protein subunit regulatory associated protein of the MTOR complex 1 (RAPTOR), the serine/threonine kinase V-Akt murine thymoma viral oncogene homolog 1 (AKT1), and the protease cathepsin H (CTSH), for which we establish a role in filaggrin expression and processing. Increased RAPTOR levels correlated with decreased filaggrin expression in patients with AD. In keratinocyte cell cultures RAPTOR upregulation or AKT1 short hairpin RNA knockdown reduced expression of the protease CTSH. Skin of CTSH-deficient mice and CTSH short hairpin RNA knockdown keratinocytes showed reduced filaggrin processing, and the mouse had both impaired skin barrier function and a mild proinflammatory phenotype.

Conclusion

Our findings highlight a novel and potentially treatable signaling axis controlling filaggrin expression and processing that is defective in patients with AD.

El texto completo de este artículo está disponible en PDF.

Graphical abstract




El texto completo de este artículo está disponible en PDF.

Key words : Atopic dermatitis, skin barrier, filaggrin, regulatory associated protein of the MTOR complex 1, protease

Abbreviations used : AD, AKT1, CTSH, EM, FLG, GAPDH, mTORC1/2, RAPTOR, REK, RXRα, shRNA, SNP, WT


Esquema


 R.F.L.O. is funded by the Great Ormond Street Hospital Children's Charity. A.S.N. is funded by a British Skin Foundation studentship (2018s). C.C. is funded as part of the Centre for Dermatology and Genetic Medicine, University of Dundee Wellcome Trust Strategic Award (098439/Z/12/Z). S.J.B. is supported by a Wellcome Trust Senior Research Fellowship in Clinical Science (106865/Z/15/Z) and a research grant from the Manknell Charitable Trust.
 Disclosure of potential conflict of interest: C. Cole's and W. O. Cookson's institutions have received a grant from Wellcome Trust. S. J. Brown's institution has received a grant from Wellcome Trust Senior Research Fellowship in Clinical Science, Tayside Dermatological Research Charity, and Manknell Charitable Trust; has received board memberships from Wellcome Trust and the British Journal of Dermatology; has received consultancy fees from CXR Biosciences; has received payment for lectures from the American Academy of Allergy, Asthma & Immunology; and has submitted a patent application (GB 1602011.7). The rest of the authors declare that they have no relevant conflicts of interest.


© 2016  The Authors. Publicado por Elsevier Masson SAS. Todos los derechos reservados.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 139 - N° 4

P. 1228-1241 - avril 2017 Regresar al número
Artículo precedente Artículo precedente
  • Six-transmembrane epithelial antigens of the prostate comprise a novel inflammatory nexus in patients with pustular skin disorders
  • Yun Liang, Xianying Xing, Maria A. Beamer, William R. Swindell, Mrinal K. Sarkar, Liza Wolterink Roberts, John J. Voorhees, J. Michelle Kahlenberg, Paul W. Harms, Andrew Johnston, Johann E. Gudjonsson
| Artículo siguiente Artículo siguiente
  • Epicutaneous immunotherapy for the treatment of peanut allergy in children and young adults
  • Stacie M. Jones, Scott H. Sicherer, A. Wesley Burks, Donald Y.M. Leung, Robert W. Lindblad, Peter Dawson, Alice K. Henning, M. Cecilia Berin, David Chiang, Brian P. Vickery, Robbie D. Pesek, Christine B. Cho, Wendy F. Davidson, Marshall Plaut, Hugh A. Sampson, Robert A. Wood, Consortium of Food Allergy Research

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2025 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.